DAIICHI SANKYO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI SANKYO, and what generic alternatives to DAIICHI SANKYO drugs are available?
DAIICHI SANKYO has three approved drugs.
There are twenty-five US patents protecting DAIICHI SANKYO drugs.
There are three hundred and nineteen patent family members on DAIICHI SANKYO drugs in forty-five countries and seventeen supplementary protection certificates in fifteen countries.
Summary for DAIICHI SANKYO
| International Patents: | 319 |
| US Patents: | 25 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| PTAB Cases with DAIICHI SANKYO as patent owner: | See PTAB cases with DAIICHI SANKYO as patent owner |
Drugs and US Patents for DAIICHI SANKYO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | 7,365,205 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | 9,169,250 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 9,555,040 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | 9,358,235 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for DAIICHI SANKYO Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Peru | 20081226 | ⤷ Try a Trial |
| Japan | 2018515490 | ⤷ Try a Trial |
| New Zealand | 595382 | ⤷ Try a Trial |
| China | 101652139 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for DAIICHI SANKYO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1405852 | 132016000024022 | Italy | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN, UN SUO SALE, UN SUO SOLVATO O UN SUO N-OSSIDO, IN PARTICOLARE EDOXABAN TOSILATO(LIXIANA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/993/001-028, 20150623 |
| 1405852 | 612 | Finland | ⤷ Try a Trial | |
| 2140867 | C20180004 00246 | Estonia | ⤷ Try a Trial | PRODUCT NAME: EDOKSABAAN;REG NO/DATE: EU/1/15/993 23.06.2015 |
| 2140867 | PA2018005,C2140867 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
